258 related articles for article (PubMed ID: 16129847)
1. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
2. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis.
Cavazzini F; Hernandez JA; Gozzetti A; Russo Rossi A; De Angeli C; Tiseo R; Bardi A; Tammiso E; Crupi R; Lenoci MP; Forconi F; Lauria F; Marasca R; Maffei R; Torelli G; Gonzalez M; Martin-Jimenez P; Maria Hernandez J; Rigolin GM; Cuneo A
Br J Haematol; 2008 Aug; 142(4):529-37. PubMed ID: 18547320
[TBL] [Abstract][Full Text] [Related]
7. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
8. Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR.
Htwe SS; Maeda M; Matsumoto R; Sakamoto N; Murakami S; Yamamoto S; Katoh M; Kumagai N; Hayashi H; Nishimura Y; Ohkura M; Wada H; Taniwaki M; Sugihara T; Otsuki T
Int J Mol Med; 2011 Jun; 27(6):789-94. PubMed ID: 21399865
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
Akervall J; Borg A; Dictor M; Jin C; Jin Y; Tanner M; Isola J; Mertens F; Wennerberg J
Int J Oncol; 2002 Jan; 20(1):45-52. PubMed ID: 11743641
[TBL] [Abstract][Full Text] [Related]
10. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
[TBL] [Abstract][Full Text] [Related]
11. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
12. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.
Fenton JA; Pratt G; Rawstron AC; Sibley K; Rothwell D; Yates Z; Dring A; Richards SJ; Ashcroft AJ; Davies FE; Owen RG; Child JA; Morgan GJ
Oncogene; 2003 Feb; 22(7):1103-13. PubMed ID: 12592397
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
14. Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.
Takimoto M; Ogawa K; Kato Y; Saito T; Suzuki T; Irei M; Shibuya Y; Suzuki Y; Kato M; Inoue Y; Takahashi M; Sugimori H; Miura I
Int J Hematol; 2008 Apr; 87(3):260-5. PubMed ID: 18274833
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Lombardi L; Poretti G; Mattioli M; Fabris S; Agnelli L; Bicciato S; Kwee I; Rinaldi A; Ronchetti D; Verdelli D; Lambertenghi-Deliliers G; Bertoni F; Neri A
Genes Chromosomes Cancer; 2007 Mar; 46(3):226-38. PubMed ID: 17171682
[TBL] [Abstract][Full Text] [Related]
16. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint.
Boersma-Vreugdenhil GR; Kuipers J; Van Stralen E; Peeters T; Michaux L; Hagemeijer A; Pearson PL; Clevers HC; Bast BJ
Br J Haematol; 2004 Aug; 126(3):355-63. PubMed ID: 15257707
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
[TBL] [Abstract][Full Text] [Related]
18. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.
Largo C; Alvarez S; Saez B; Blesa D; Martin-Subero JI; González-García I; Brieva JA; Dopazo J; Siebert R; Calasanz MJ; Cigudosa JC
Haematologica; 2006 Feb; 91(2):184-91. PubMed ID: 16461302
[TBL] [Abstract][Full Text] [Related]
19. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.
Smadja NV; Leroux D; Soulier J; Dumont S; Arnould C; Taviaux S; Taillemite JL; Bastard C
Genes Chromosomes Cancer; 2003 Nov; 38(3):234-9. PubMed ID: 14506697
[TBL] [Abstract][Full Text] [Related]
20. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]